118156-56-2

Usage

Uses

Used in Pharmaceutical Industry:
N-ethoxycarbonyl-4-piperidinemethanol is used as a reagent for the synthesis of various pharmaceutical compounds due to its ability to undergo multiple chemical transformations, which is essential in the creation of diverse medicinal agents.
Used in Organic Synthesis:
In the field of organic synthesis, N-ethoxycarbonyl-4-piperidinemethanol is utilized as a versatile building block. Its ethoxycarbonyl group allows for a range of reactions that can lead to the formation of complex organic molecules, contributing to the advancement of chemical research and development.
Used as a Precursor in Organic Chemistry:
N-ethoxycarbonyl-4-piperidinemethanol is also used as a precursor in the synthesis of other important organic chemicals. Its presence in the molecular structure facilitates the creation of new compounds that can have various applications across different industries.

Upstream product

• 6457-49-4 4-piperidinemethanol 
• 541-41-3 chloroformic acid ethyl ester 
• 90748-01-9 4-piperidinemethanol hydrochloride 
• 118133-15-6 1-ethoxycarbonylpiperidine-4-carboxylic acid 
• 67-66-3 chloroform 
• 121-44-8 triethylamine 

Downstream Products

• 99658-58-9 ethyl 4-formylpiperidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent

A series of novel benzamide derivatives, altering the 4-fluorophenylalkyl moiety in cisapride, were synthesized as 5-HT4 receptor agonists, and SAR of these analogs was examined on in vitro and in vivo prokinetic activities. These compounds were synthesized for high 5-HT4 receptor binding affinities and low hERG affinities. Several types of analogs were obtained and screened for 5-HT4 binding, hERG blocking, agonism, and gastric emptying assessment. Among the analogues, compound 23g showed promising results compared with the other analogs with respect to gastric emptying rates in rats. Therefore, we suggest that it may be a clinical candidate for the development of a potent prokinetic agent to treat GI disorders.

NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF

The present invention provides a novel benzamide derivative represented by formula 1 and an isomer, a pharmaceutically acceptable salt or hydrate thereof, and a composition for activating a 5-HT4 receptor comprising the same, as an active ingredi

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention provides a novel benzamide derivative represented by formula 1 and an isomer, a pharmaceutically acceptable salt or hydrate thereof, and a composition for activating a 5-HT4 receptor comprising the same, as an active ingre

Modulators of muscarinic receptors

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarnic receptors of formula (I). The present invention also provides impositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Antipicornaviral pyridazinamines

Piperidinyl, pyrrolidinyl, azepinyl and piperazinyl pyridazines of formula STR1 wherein one or two carbon atoms of the STR2 moiety may be substituted with C1-4 alkyl, C1-4 alkyloxy or two carbon atoms of the CH2 groups of said moiety may be bridged with a C2-4 alkanediyl radical; X represents CH or N; R1 represents hydrogen, C1-4 alkyl, halo, hydroxy, trifluoromethyl, cyano, C1-4 alkyloxy, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, C1-4 alkyloxycarbonyl, C1-4 alkylcarbonyl or aryl; R2 and R3 each independently represent hydrogen or C1-4 alkyl; Alk represents C1-4 alkanediyl; R4 and R5 each independently represent hydrogen, C1-4 alkyl or halo; and Het represents STR3 the addition salts and stereochemically isomeric forms thereof, said compounds having antipicornaviral activity. Pharmaceutical compositions containing these compounds as active ingredient, and a method of preparing said compounds and pharmaceutical compositions.

Saturated heterocyclic carboxamide derivatives

A saturated heterocyclic carboxamide derivative of the following general formula (I) and salts thereof which have platelet activating factor (PAF) antagonizing activity. STR1